ReviewCancer chemotherapy and pharmacology2026
Synergistic interactions and optimal sequencing of chemotherapy and immunotherapy in cancer treatment.
Review in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The interplay between oncolytic viruses, Toll-like receptor signaling, and chemotherapy in overcoming tumor immune tolerance.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chemotherapy and immunotherapy are now both crucial methods for combating cancers. However, the interplay between immunotherapy and chemotherapy is highly intricate, and varying combinations and sequencing of treatment may produce distinct therapeutic outcomes. Chemotherapy, with its cytotoxic effect, may trigger immunogenic cell death and alter the tumor microenvironment, hence affecting immune responses. On the other hand, immunotherapy may potentially enhance the effectiveness of chemotherapy by eliminating cancer cells via the stimulation of the immune system. This article focuses on the effect of treatment sequence on efficacy, which is less systematically discussed in the current literature. We deeply analyzed the synergistic potential of chemotherapy and immunotherapy and explored how these two modalities can enhance each other to improve treatment efficacy. By summarizing the latest research results, we elucidated their interaction mechanisms and emphasized the potential advantages of sequential treatment. Integrating these insights aims to provide clinicians with novel therapeutic concepts, consequently optimizing therapy strategies and augmenting the prognosis for cancer patients.
Indexed as
Identifiers
41729286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.